scientific-skills/clinical-reports/references/clinical_trial_reporting.md
The International Council for Harmonisation (ICH) E3 guideline defines the structure and content of clinical study reports (CSRs) for regulatory submission.
Purpose:
Audience:
Length: Typically 50-300 pages (main text), with extensive appendices
Required elements:
Length: 5-15 pages
Content:
Standard synopsis elements:
3.1 Independent Ethics Committee/Institutional Review Board
3.2 Ethical Conduct of Study
3.3 Patient Information and Consent
4.1 Investigators
4.2 Administrative Structure
4.3 Study Monitoring and Quality Assurance
5.1 Background
5.2 Investigational Product
5.3 Non-Investigational Therapy
6.1 Primary Objective
6.2 Secondary Objectives
6.3 Endpoints
7.1 Overall Study Design and Plan
7.2 Sample Size
7.3 Statistical Methods
7.4 Changes to Protocol
8.1 Inclusion and Exclusion Criteria
8.2 Demographic and Baseline Characteristics
8.3 Patient Disposition
8.4 Protocol Deviations
8.5 Demographic and Other Baseline Characteristics
9.1 Data Sets Analyzed
9.2 Demographic and Baseline Characteristics
9.3 Measurements of Treatment Compliance
9.4 Efficacy Results
9.4.1 Primary Endpoint
9.4.2 Secondary Endpoints
9.4.3 Other Efficacy Endpoints
9.5 Dropouts and Missing Data
10.1 Extent of Exposure
10.2 Adverse Events
10.2.1 Overview of Adverse Events
10.2.2 Common Adverse Events
10.2.3 Serious Adverse Events
10.2.4 Adverse Events Leading to Discontinuation
10.2.5 Deaths
10.3 Clinical Laboratory Evaluations
10.4 Vital Signs and Physical Findings
10.5 ECG Evaluation
10.6 Special Safety Evaluations
11.1 Efficacy Discussion
11.2 Safety Discussion
11.3 Benefit-Risk Assessment
11.4 Clinical Implications
Comprehensive set of tables and figures for efficacy and safety data.
Common tables:
Common figures:
Required appendices:
Optional appendices:
SAP Components:
SAP Timing:
CONSORT guidelines promote transparent and complete reporting of randomized controlled trials.
Standard format showing patient flow through trial:
Assessed for eligibility (n=)
↓
Randomized (n=)
├─ Allocated to intervention (n=)
│ ├─ Received intervention (n=)
│ └─ Did not receive intervention (n=)
│ Give reasons
├─ Allocated to control (n=)
│ ├─ Received control (n=)
│ └─ Did not receive control (n=)
│ Give reasons
↓
Lost to follow-up (n=)
Give reasons
Discontinued intervention (n=)
Give reasons
↓
Analyzed (n=)
Excluded from analysis (n=)
Give reasons
An adverse event or suspected adverse reaction is considered serious if it:
1. Administrative Information
2. Patient Information (De-identified)
3. Study Information
4. Event Information
5. Seriousness Criteria
6. Severity
Note: Severity ≠ Seriousness
7. Outcome
8. Causality Assessment
9. Expectedness
10. Action Taken with Study Drug
11. Treatments/Interventions for Event
12. Event Narrative
Example narrative:
A 58-year-old male (Subject ID: 12345) enrolled in Study XYZ-301, a Phase 3
randomized trial of Drug X vs. placebo for heart failure. On Day 42 of treatment
(15-Feb-2024), the patient presented to the emergency department with sudden onset
severe chest pain, diaphoresis, and dyspnea. ECG showed ST-segment elevation in
leads V2-V4. Troponin I was elevated at 12.5 ng/mL (normal <0.04). The patient was
diagnosed with acute ST-elevation myocardial infarction and underwent emergent
cardiac catheterization revealing 95% occlusion of the left anterior descending
artery. Percutaneous coronary intervention with drug-eluting stent placement was
performed successfully. The patient was admitted to the cardiac intensive care unit.
Study drug was permanently discontinued on Day 42. The patient recovered and was
discharged on Day 47 (20-Feb-2024) in stable condition. This event was assessed as
unlikely related to study drug by the investigator, as the patient had significant
underlying coronary artery disease risk factors including diabetes, hypertension,
and smoking history.
FDA IND Safety Reporting (21 CFR 312.32):
EMA Expedited Reporting:
IRB Reporting:
MedDRA (Medical Dictionary for Regulatory Activities):
Example:
WHO-UMC Causality Categories:
Naranjo Algorithm (for ADRs): Scoring system based on 10 questions:
Purpose:
DSMB Charter Elements:
DSMB Reports:
This reference provides comprehensive guidance for clinical trial reporting following ICH-E3 and CONSORT guidelines, as well as SAE reporting requirements. Use these standards when preparing regulatory submissions and trial publications.